glp 1 agonist after cholecystectomy ACG 2025 Annual Meeting

Trends in the Development of GLP-1 Receptor Agonists

Retatrutide - A GAME CHANGER in weight loss and creating a major buzz in the wellness & medical world. Retatrutide is a triple-agonist peptide (GLP-1, GIP & Glucagon) that's showing some of

A new Medicare program could expand access to GLP-1 weight-loss medications starting in 2026. For Med Spas offering physician-supervised GLP -1 programs, this could lead to more patients asking about eligibility and

Novo Nordisk's Wegovy pill (oral semaglutide 25 mg, once daily) has just been approved by the US FDA as the first oral GLP1 receptor agonist for longterm weight management and CV risk

PDF) Efficacy and safety of glucagonlike peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials